Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

First patient treated in trial of Renevia in HIV-associated lipoatrophy

Feb. 25, 2015

HIV Vaccine Trials Network launches phase I/II trial of prime-boost vaccine

Feb. 23, 2015

New HIV protease inhibitors disclosed by Merck & Co.

Feb. 20, 2015

Novel anti-HIV agent shows potential as HIV vaccine alternative

Feb. 20, 2015

NeED Pharma presents new viral entry inhibitors

Feb. 12, 2015

Gilead presents new anti-HIV compounds

Feb. 6, 2015

CytoDyn concludes phase II PRO-140 trial and submits phase III protocol to FDA

Feb. 5, 2015

Prezcobix approved in the U.S. for the treatment of adults with HIV-1

Feb. 2, 2015

EMA CHMP recommends approval of lamivudine/raltegravir for HIV-1 infection

Jan. 27, 2015

Laboratoire Biodim tests novel agents for HIV

Jan. 21, 2015

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...